Table I.
Summary of studies that assessed MMP-9 inhibitors in the treatment of HCC.
| Model | Summary | Cell type | (Refs.) |
|---|---|---|---|
| Human | Diosmetin downregulates MMP-9, leading to the inhibition of migration and invasion of HCC cells | SK-HEP-1 | (69) |
| Niclosamide downregulates MMP-9, leading to the suppression of HCC cell migration | HLF and PLC/PRF/5 | (70) | |
| Retinoic acid-induced protein I inhibits the migration and invasion of HCC cells by decreasing MMP-9 levels | Liver cells | (71) | |
| MicroRNA-133a targets MMP-9, and prevents HCC cell proliferation, migration and invasion | HepG2 and SMMC-7721 | (72) | |
| The antibiotic salinomycin blocks the invasion and migration of HCC cells through JNK/JunD-mediated MMP-9 expression | HCCLM3 | (73) | |
| Glabridin inhibits the invasion of human HCC cells, and may act as a chemopreventive agent against liver cancer metastasis | Huh7 and Sk-Hep-1 | (74) | |
| Mice | Tanshinone II-A prevents the invasion and metastasis of HCC cells by blocking the activity of MMP-9 | Liver cells | (75) |
| Rat | Epigallocatechin-gallate blocks MMP-9 activity, leading to hepatoprotective and chemoprotective effects | Liver cells | (76) |
| Doxycycline produces hepatoprotective and antitumor activity by blocking MMP-9 | Liver cells | (77) |
MMP, matrix metalloproteinase; HCC, hepatocellular carcinoma.